Simple blood test may spot heart risk in preemies
NCT ID NCT07338370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether levels of a substance called PGE2 in the blood can predict which premature babies (born at 32 weeks or earlier) will develop a serious heart condition called patent ductus arteriosus (PDA). Researchers will measure PGE2 levels and use heart ultrasounds in 34 infants. Some babies will receive ibuprofen to close the duct, while others are observed. The goal is to find a way to identify high-risk infants early.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ibuprofen
- What this could lead to
- If successful, this could help doctors identify which preterm infants are at risk for a serious heart condition, allowing earlier treatment.
- What could go wrong
- This is a small, early observational study. Results may not apply to all preterm infants, and the link between PGE2 levels and PDA may not be strong enough to guide treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL PREMATURITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine, Ain Shams, University
RECRUITINGCairo, Abbasia, 11517, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.